Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
11/09/2022* -- Results Q3 2022 -- -0.41 --
11/09/2022* 17:00 EST Earnings Call Q3 2022 -- -- --
08/09/2022 -- Results Q2 2022 -0.44 -0.50 11.22%
08/09/2022 17:00 EST Earnings Call Q2 2022 -- -- --
05/05/2022 -- Results Q1 2022 -0.55 -0.43 -28.49%
05/05/2022 17:00 EST Earnings Call Q1 2022 -- -- --
03/01/2022 -- Results Q4 2021 -0.58 -0.55 -4.69%
03/01/2022 17:00 EST Earnings Call Q4 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 11/09/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 08/09/2022
Beat/Miss Upgrade
Return Since 0.16%
Last FQE 06/30/2022
Next FQE 09/30/2022

Profile

Edit
ChemoCentryx Inc is a biopharmaceutical company involved in the discovery, development, and commercialization of orally administered drugs to treat rare diseases, inflammatory disorders, autoimmune diseases, and cancer. The company's approach is to target the chemoattractant system, defined as a network of molecules (for example, chemokine ligands, their associated receptors, and chemoattractant receptors) known to cause inflammation. The targeted therapeutic areas are an antineutrophil cytoplasmic antibody, atypical hemolytic uremic syndrome, immunoglobulin A-mediated nephropathy (rare diseases category), pancreatic cancer, chronic kidney disease, psoriasis, rheumatoid arthritis, asthma, Crohn's disease, inflammatory bowel disease, and others.
URL https://www.chemocentryx.com
Investor Relations URL https://ir.chemocentryx.com/
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Blend
Next Earnings Release Nov. 09, 2022 (est.)
Last Earnings Release Aug. 09, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
18.59%
-8.64%
-19.59%
83.36%
262.5%
56.56%
-41.20%
39.71%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-10.85%
3.97%
-7.55%
22.25%
15.17%
27.62%
-2.00%
0.87%
13.92%
36.36%
-41.67%
-81.67%
-92.16%
-85.11%
-87.99%
-43.69%
-33.44%
--
--
--
--
--
--
--
--
-6.43%
-55.61%
87.17%
67.74%
93.99%
62.70%
150.2%
-66.28%
As of August 10, 2022.

Profile

Edit
ChemoCentryx Inc is a biopharmaceutical company involved in the discovery, development, and commercialization of orally administered drugs to treat rare diseases, inflammatory disorders, autoimmune diseases, and cancer. The company's approach is to target the chemoattractant system, defined as a network of molecules (for example, chemokine ligands, their associated receptors, and chemoattractant receptors) known to cause inflammation. The targeted therapeutic areas are an antineutrophil cytoplasmic antibody, atypical hemolytic uremic syndrome, immunoglobulin A-mediated nephropathy (rare diseases category), pancreatic cancer, chronic kidney disease, psoriasis, rheumatoid arthritis, asthma, Crohn's disease, inflammatory bowel disease, and others.
URL https://www.chemocentryx.com
Investor Relations URL https://ir.chemocentryx.com/
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Blend
Next Earnings Release Nov. 09, 2022 (est.)
Last Earnings Release Aug. 09, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
PBE 14.40M USD 5.39%
F00001CY0W 374.00 USD 3.74%
SBIO 2.180M USD 1.77%
XBI 152.67M USD 1.74%
BIOACX 168.00 USD 1.68%
JUSOX 4.594M USD 1.66%
IHE 4.256M USD 0.96%
FBIOX 45.09M USD 0.93%
LABU 11.85M USD 0.87%
FIJYX 13.58M USD 0.85%
IWC 6.794M USD 0.68%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter CCXI Tweets